Phase I study on the safety, pharmacokinetic profile, and efficacy of the combination of TSU-68, an oral antiangiogenic agent, and S-1 in patients with advanced hepatocellular carcinoma

Investigational New Drugs

Volumn 32, Issue 5, 2014, Pages 928-936

  Ikeda, Masafumi ^a   Shiina, Shuichiro ^b,e   Nakachi, Kohei ^a   Mitsunaga, Shuichi ^a   Shimizu, Satoshi ^a   Kojima, Yasushi ^a,c   Ueno, Hideki ^d   Morizane, Chigusa ^d   Kondo, Shunsuke ^d   Sakamoto, Yasunari ^d   Asaoka, Yoshinari ^e   Tateishi, Ryosuke ^e   Koike, Kazuhiko ^e   Arioka, Hitoshi ^f   Okusaka, Takuji ^d  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b JUNTENDO UNIVERSITY   (Japan)

^c NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^d NATIONAL CANCER CENTER HOSPITAL   (Japan)

^e UNIVERSITY OF TOKYO   (Japan)

^f YOKOHAMA ROSAI HOSPITAL   (Japan)

Author keywords

Chemotherapy; Hepatocellular carcinoma; S 1; TSU 68; VCAM 1

Indexed keywords

5-((1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDENE)METHYL)-2,4-DIMETHYL-1H-PYRROLE-3-PROPANOIC ACID; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; DRUG COMBINATION; INDOLE DERIVATIVE; OTERACIL; PROPIONIC ACID DERIVATIVE; S 1 (COMBINATION); TEGAFUR;

AGED; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIAL; DRUG COMBINATION; FEMALE; HUMAN; LIVER NEOPLASMS; MALE; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; TREATMENT OUTCOME; VERY ELDERLY;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; DRUG COMBINATIONS; FEMALE; HUMANS; INDOLES; LIVER NEOPLASMS; MALE; MIDDLE AGED; OXONIC ACID; PROPIONATES; TEGAFUR; TREATMENT OUTCOME;

EID: 84930749396     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-014-0109-2     Document Type: Article

References (28)

1. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics 2002. CA Cancer J Clin 55:74-108
2. Llovet JM, Ricci S, Mazzaferro Vet al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390
3. Cheng AL, Kang YK, Chen Z et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25-34
4. Laird AD, Vajkoczy P, Shawver LK et al (2000) SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res 60:4152-4160
5. Solorzano CC, Jung YD, Bucana CD et al (2001) In vivo intracellular signaling as a marker of antiangiogenic activity. Cancer Res 61:7048-7051
6. Kuenen BC, Giaccone G, Ruijter R et al (2005) Dose-finding study of the multitargeted tyrosine kinase inhibitor SU6668 in patients with advanced malignancies. Clin Cancer Res 11:6240-6246
7. Yorozuya K, Kubota T, Watanabe M et al (2005) TSU-68 (SU6668) inhibits local tumor growth and liver metastasis of human colon cancer xenografts via anti-angiogenesis. Oncol Rep 14:677-682
8. Naumova E, Ubezio P, Garofalo A et al (2006) The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis. Clin Cancer Res 12:1839-1849
9. Kanai F, Yoshida H, Tateishi R et al (2011) A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 67:315-324
10. InabaY, Kanai F, Aramaki Tet al (2013) A randomised phase II study of TSU-68 in patients with hepatocellular carcinoma treated by transarterial chemoembolisation. Eur J Cancer 49:2832-2840
11. Shirasaka T, Shimamoto Y, Fukushima M (1993) Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 53:4004-4009
12. Furuse J, Okusaka T, Kaneko S et al (2010) Phase I/II study of the pharmacokinetics, safety and efficacy of S-1 in patients with advanced hepatocellular carcinoma. Cancer Sci 101:2606-2611
13. Finn RS, Poon RT, Yau T et al (2013) Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma. J Hepatol 59:1271-1277
14. Lee SJ, Lee J, Park SH et al (2012) Phase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma. Invest New Drugs 30:1540-1547
15. Abou-Alfa GK, Johnson P, Knox JJ et al (2010) Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA 304:2154-2160
16. Hsu CH, Shen YC, Lin ZZ et al (2010) Phase II study of combining sorafenib withmetronomic tegafur/uracil for advanced hepatocellular carcinoma. J Hepatol 53:126-131
17. Petrini I, Lencioni M, Ricasoli M et al (2012) Phase II trial of sorafenib in combination with 5-fluorouracil infusion in advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 69:773-780
18. Hsu CH, Yang TS, Hsu C et al (2010) Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma. Br J Cancer 16:981-986
19. Kudo M, Imanaka K, Chida N et al (2011) Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with un-resectable hepatocellular carcinoma. Eur J Cancer 47:2117-2127
20. Lencioni R, Llovet JM, Han G et al (2012) Sorafenib or placebo in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC): phase II, randomized, double-blind SPACE trial. J Clin Oncol 30:154
21. Wörns MA (2013) Systemic therapy and synergies by combination. Dig Dis 31:104-111
22. Therasse P, Eisenhauer EA, Verweij J (2006) RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer 42:1031-1039
23. Llovet JM, Bruix J (2008) Novel advancements in the management of hepatocellular carcinoma. J Hepatology 48:20-37
24. Bruix J, Sherman M (2005) Management of hepatocellular carcinoma. Hepatology 42:1208-1236
25. Chen Q, Zhang XH, Massagué J (2011) Macrophage binding to receptor VCAM-1 transmits survival signals in breast cancer cells that invade the lungs. Cancer Cell 20:538-549
26. Lu X, Mu E, Wei Y et al (2011) VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging innodataalpha4innodatabeta1-positive osteoclast progenitors. Cancer Cell 20:701-714
27. Diaz-Sanchez A, Matilla A, Nuñez O et al (2013) Serum level of soluble vascular cell adhesion molecule in patients with hepatocellular carcinoma and its association with severity of liver disease. Ann Hepatol 12:236-247
28. Ho JW, Poon RT, Tong CS, Fan ST (2004) Clinical significance of serum vascular cell adhesion molecule-1 levels in patients with hepatocellular carcinoma. World J Gastroenterol 10:2014-2018